Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mankind PharmaBOM:543904 +0.33%91 Days Inventory is 178.17 as of Jun. 2026, which is 4% below its 10-year median of 186.49. GuruFocus rates BOM:543904 with a GF Score™ of 91/100 and a GF Value™ of ₹2,942.84 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Mankind Pharma ranks worse than 58.24% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Mankind Pharma's Average Total Inventories for the
three
months ended in Jun. 2026 was ₹21,445 Mil. Mankind Pharma's Cost of Goods Sold for the
three
months ended in Jun. 2026 was ₹10,983 Mil.
Hence, Mankind Pharma's Days Inventory for the
three
months ended in Jun. 2026 was 178.17.
The historical rank and industry rank for Mankind Pharma's Days Inventory or its related term are showing as below:
BOM:543904'
s Days Inventory Range Over the Past 10 Years
Min: 170.63 Med: 186.49 Max: 217.51
Current: 184.42
During the past 7 years, Mankind Pharma's highest Days Inventory was 217.51. The lowest was 170.63. And the median was 186.49.
BOM:543904's Days Inventory is ranked worse than 58.24% of 922
companies
in the Drug Manufacturers industry
Industry Median: 165.005
vs BOM:543904: 184.42
Mankind Pharma's Days Inventory
declined
from Jun. 2025 (181.33) to Jun. 2026 (178.17).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Mankind Pharma's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.51.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Mankind Pharma's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.53.
Mankind Pharma (BOM:543904) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Mankind Pharma's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Mankind Pharma's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Mankind Pharma Days Inventory Related Terms
Mankind Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Mankind Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mankind Pharma Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Mankind Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mankind Pharma (BOM:543904) has a Days Inventory of 178.17 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Mankind Pharma and its competitors. This is near median its historical median of 186.49. Over the past decade, Mankind Pharma's Days Inventory has ranged from 170.63 to 217.51. According to the industry distribution chart, Mankind Pharma ranks #537 out of 922 companies in the Drug Manufacturers industry, placing it in the top 58.2%.
Is Mankind Pharma's Days Inventory too high?
Mankind Pharma's current Days Inventory of 178.17 is near median its 10-year median of 186.49. Over the past 10 years, this metric has ranged from a low of 170.63 to a high of 217.51. The Drug Manufacturers industry median Days Inventory is 165.01. Mankind Pharma's value of 178.17 is 8% above this industry median. Based on the distribution chart, Mankind Pharma ranks #537 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Mankind Pharma has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mankind Pharma ranks #537 out of 922 companies for Days Inventory. This places Mankind Pharma in the lower half of its industry. The industry median Days Inventory is 165.01. Mankind Pharma's value of 178.17 is 8% above this benchmark. Historically, Mankind Pharma's own Days Inventory has ranged from 170.63 to 217.51 over the past decade. While the company's 10-year median is 186.49 vs. the industry median of 165.01, Mankind Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 165.01, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mankind Pharma's current Days Inventory of 178.17 is 8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Mankind Pharma and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 165.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mankind Pharma's current Days Inventory is 178.17, which is near median its own 10-year median of 186.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,942.84, compared to a current price of ₹2,439.00 — trading 17.1% below its estimated fair value. The current Days Inventory is 178.17, which is near median its 10-year median of 186.49 and 8% above the Drug Manufacturers industry median of 165.01. Mankind Pharma's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current Days Inventory is 178.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mankind Pharma (BOM:543904) Overvalued in 2026?
Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued.
The current stock price of ₹2,439.00 is trading 17.1% below its estimated GF Value™ of ₹2,942.84.
GuruFocus considers Mankind Pharma to be Modestly Undervalued.
Key valuation signals for BOM:543904:
Days Inventory: 178.17 (near median its 10-year median of 186.49)
GF Value™: ₹2,942.84 vs. price of ₹2,439.00 (17.1% below fair value)
Industry Position: 8% above the Drug Manufacturers median (#537 of 922)
No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
91GF Score
Get the complete analysis for BOM:543904
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543904 has been successfully added to your 
